IMCD Stock Analysis: IMCD | AS
Specialty Chemicals | AS, Netherlands | Market Cap: 5.568m EUR | 12M Return: 10.4% | NL0010801007 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 11.9M
EPS Trend: -2.4%
Rev. Trend: 95.3%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
IMCD N.V. is a global specialty chemicals and ingredients distributor, marketing and selling a broad portfolio to customers across Europe, the Middle East, Africa, North America, South America, and the Asia-Pacific. Rather than manufacturing chemicals itself, the company acts as an intermediary between chemical producers and downstream formulators, serving end-markets such as advanced materials (adhesives, plastics, rubber, composites), personal care and beauty, food and nutrition, and home care and industrial cleaning. The product range spans additives, pigments, solvents, surfactants, emulsifiers, UV filters, and active ingredients, as well as lubricant components and oil, gas, and energy solutions for upstream, midstream, and downstream applications.
The company was founded in 1995 and is headquartered in Rotterdam, the Netherlands, and is classified within the Trading Companies & Distributors sub-industry. Specialty chemical distributors like IMCD typically earn margins by combining logistics, technical support, and formulation expertise, adding value beyond pure commodity resale by helping customers select and apply the right ingredients for their specific applications.
- Bolt-on acquisitions fuel consistent double-digit revenue growth across regions
- Specialty margins expand as high-value ingredients outpace commodity distribution volumes
- Personal care and pharma demand offsets softer industrial chemicals end markets
| Net Income: 230.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 2.58 > 1.0 |
| NWC/Revenue: 10.99% < 20% (prev 16.50%; Δ -5.51% < -1%) |
| CFO/TA 0.08 > 3% & CFO 384.0m > Net Income 230.2m |
| Net Debt (1.66b) to EBITDA (532.2m): 3.13 < 3 |
| Current Ratio: 1.35 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.0m) vs 12m ago 3.68% < -2% |
| Gross Margin: 9.75% > 18% (prev 18.72%; Δ -8.97% > 0.5%) |
| Asset Turnover: 103.3% > 50% (prev 104.4%; Δ -1.09% > 0%) |
| Interest Coverage Ratio: 4.64 > 6 (EBIT TTM 385.4m / Interest Expense TTM 83.1m) |
| A: 0.11 (Total Current Assets 2.11b - Total Current Liabilities 1.56b) / Total Assets 4.95b |
| B: 0.21 (Retained Earnings 1.04b / Total Assets 4.95b) |
| C: 0.08 (EBIT TTM 385.4m / Avg Total Assets 4.79b) |
| D: 0.75 (Book Value of Equity 2.12b / Total Liabilities 2.82b) |
| Altman-Z'' = 2.74 = A |
| DSRI: 1.15 (Receivables 1.08b/916.4m, Revenue 4.94b/4.83b) |
| GMI: 1.92 (GM 18.72% / 9.75%) |
| AQI: 0.96 (AQ_t 0.54 / AQ_t-1 0.57) |
| SGI: 1.02 (Revenue 4.94b / 4.83b) |
| TATA: -0.03 (NI 230.2m - CFO 384.0m) / TA 4.95b) |
| Beneish M = -2.08 (Cap -4..+1) = BB |
As of September 27, 2026, the stock is trading at EUR 95.90 with a total of 113,354 shares traded. Over the past week, the price has changed by +2.79%, over one month by +0.40%, over three months by +18.19% and over the past year by +10.35%.
Current recommended Stop Loss: 93.00 (which is 3% or 1.2 ATR below the current price).
IMCD has no consensus analysts rating.
P/E Trailing = 24.2416
P/E Forward = 14.1243
P/S = 1.1204
P/B = 2.6472
Revenue TTM = 4.94b EUR
EBIT TTM = 385.4m EUR
EBITDA TTM = 532.2m EUR
Long Term Debt = 1.29b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 734.0m EUR (from shortTermDebt, last quarter)
Debt = 1.91b EUR (from shortLongTermDebtTotal, last quarter) + Leases 104.2m
Net Debt = 1.66b EUR (calculated: Debt 1.91b - CCE 248.7m)
Enterprise Value = 7.23b EUR (5.57b + Debt 1.91b - CCE 248.7m)
Interest Coverage Ratio = 4.64 (Ebit TTM 385.4m / Interest Expense TTM 83.1m)
EV/FCF = 19.52x (Enterprise Value 7.23b / FCF TTM 370.4m)
FCF Yield = 5.12% (FCF TTM 370.4m / Enterprise Value 7.23b)
FCF Margin = 7.49% (FCF TTM 370.4m / Revenue TTM 4.94b)
Net Margin = 4.66% (Net Income TTM 230.2m / Revenue TTM 4.94b)
Gross Margin = 9.75% ((Revenue TTM 4.94b - Cost of Revenue TTM 4.46b) / Revenue TTM)
Gross Margin QoQ = 10.61% (prev 8.77%)
Tobins Q-Ratio = 1.46 (Enterprise Value 7.23b / Total Assets 4.95b)
Interest Expense / Debt = 4.34% (Interest Expense 83.1m / Debt 1.91b)
Taxrate = 26.49% (82.9m / 313.1m)
NOPAT = 283.4m (EBIT 385.4m * (1 - 26.49%))
Current Ratio = 1.35 (Total Current Assets 2.11b / Total Current Liabilities 1.56b)
Debt / Equity = 0.90 (Debt 1.91b / totalStockholderEquity, last quarter 2.12b)
Debt / EBITDA = 3.13 (Net Debt 1.66b / EBITDA 532.2m)
Debt / FCF = 4.49 (Net Debt 1.66b / FCF TTM 370.4m)
Total Stockholder Equity = 2.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.81% (Net Income 230.2m / Total Assets 4.95b)
RoE = 11.02% (Net Income TTM 230.2m / Total Stockholder Equity 2.09b)
RoCE = 11.41% (EBIT 385.4m / Capital Employed (Equity 2.09b + L.T.Debt 1.29b))
RoIC = 7.33% (NOPAT 283.4m / Invested Capital 3.87b)
WACC = 6.39% (E(5.57b)/V(7.48b) * Re(7.49%) + D(1.91b)/V(7.48b) * Rd(4.34%) * (1-Tc(0.26)))
Discount Rate = 7.49% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 83.47 | Cagr: 1.47%
[DCF] Terminal Value 77.97% ; FCFF base≈313.1m ; Y1≈358.9m ; Y5≈528.2m
[DCF] Fair Price = 106.4 (EV 7.95b - Net Debt 1.66b = Equity 6.28b / Shares 59.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -2.45 | EPS CAGR: -0.19% | SUE: N/A | # QB: 0
Revenue Correlation: 95.28 | Revenue CAGR: 4.14% | SUE: 1.88 | # QB: 1
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=6.01 | Chg30d=+1.97% | Revisions=+46% | GrowthEPS=+15.8% | GrowthRev=+8.2%
EPS next Year (2027-12-31): EPS=6.47 | Chg30d=+1.44% | Revisions=+62% | GrowthEPS=+7.6% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +61% (up=17, down=3)